Overview

Palliative Management of Inoperable Malignant Bowel Obstruction

Status:
Recruiting
Trial end date:
2023-03-07
Target enrollment:
Participant gender:
Summary
To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Metoclopramide
Octreotide